Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin
- 6 January 2011
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 40 (6) , 1322-1331
Abstract
The behaviour of the antimetastatic Ru(III) complex imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) under physiological conditions and its interactions with human serum albumin (hsA) have been studied using electron paramagnetic resonance spectroscopy (EPR). In physiological buffer at pH 7.4, these experiments demonstrate that the DMSO ligand is replaced rapidly by water, and spectra from the subsequent formation of five other Ru(III) complexes show further aquation processes. Although EPR spectra from mono-nuclear Ru(III) complexes are visible after 24 h in buffer, a significant decrease in the overall signal intensity following the first aquation step is consistent with the formation of oxo-bridged Ru(III) oligomers. Incubation with hsA reveals very rapid binding to the proteinvia hydrophobic interactions. This is followed by coordination through ligand exchange with protein side chains, likely with histidine imidazoles and at least one other specific site. Similar behaviour is observed when the complex is incubated in human serum, indicating that hsA binding dominates speciation in vivo. The addition of ascorbic acid to NAMI-A in buffer leads to quantitative reduction, producing EPR-silent Ru(II) complexes. However, this process is prevented when the complex binds coordinatively to hsA. Together, these results demonstrate the key role that hsA plays in defining the species found in vivo following intravenous treatment with NAMI-A, through prevention of oligomerization and maintenance of the oxidation state, to give protein-bound mono-nuclear Ru(III) species.Keywords
This publication has 58 references indexed in Scilit:
- Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic ActivityAngewandte Chemie International Edition, 2010
- Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPRJBIC Journal of Biological Inorganic Chemistry, 2009
- Electronic structural investigations of ruthenium compounds and anticancer prodrugsJBIC Journal of Biological Inorganic Chemistry, 2009
- The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albuminJBIC Journal of Biological Inorganic Chemistry, 2008
- Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome cJBIC Journal of Biological Inorganic Chemistry, 2007
- Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-AEuropean Journal of Cancer, 2004
- Pharmacological Effects of the Ruthenium Complex NAMI‐A Given Orally to CBA Mice With MCa Mammary CarcinomaMetal-Based Drugs, 2001
- Treatment of residual metastases with Na[trans-RuCl4(DMSO)lm] and ruthenium uptake by tumor cellsAnti-Cancer Drugs, 1996
- Redox regulation of maize NADP-malic enzyme by thiol-disulfide interchange: effect of reduced thioredoxin on activityBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1994
- The Availability of the Disulfide Bonds of Human and Bovine Serum Albumin and of Bovine γ-Globulin to Reduction by Thioglycolic AcidJournal of the American Chemical Society, 1957